MESOTHELIN AND CD137 BINDING MOLECULES

To solve the problem in which clinical development of CD137 agonist molecules has been held back because of treatment being associated with either dose-limiting high-grade liver inflammation (urelumab) or low clinical efficacy (utomilumab).SOLUTION: The present invention relates to antibody molecule...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JOSE MUNOZ-OLAYA, FRANCISCA WOLLERTON, NEIL BREWIS, REMI FERTIN, CLAIRE READER, MIHRIBAN TUNA
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To solve the problem in which clinical development of CD137 agonist molecules has been held back because of treatment being associated with either dose-limiting high-grade liver inflammation (urelumab) or low clinical efficacy (utomilumab).SOLUTION: The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.SELECTED DRAWING: None 【課題】ＣＤ１３７アゴニスト分子の臨床開発は、用量を制限する高グレードの肝臓の炎症（ウレルマブ）又は低い臨床効果（ウトミルマブ）のいずれかに関連する処置のため、阻止されてきた。【解決手段】本発明は、メソテリン（ＭＳＬＮ）及びＣＤ１３７の両方に結合する抗体分子に関する。抗体分子は、ＭＳＬＮのＣＤＲベースの結合部位と、抗体分子の定常ドメインに位置するＣＤ１３７抗原結合部位とを含む。抗体分子は、例えば、癌の処置に用途が見出される。【選択図】なし